| Bioactivity | (R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations[1]. | ||||||||||||
| Name | (R)-Pirtobrutinib | ||||||||||||
| CAS | 2101700-14-3 | ||||||||||||
| Formula | C22H21F4N5O3 | ||||||||||||
| Molar Mass | 479.43 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644. |
(R)-Pirtobrutinib
CAS: 2101700-14-3 F: C22H21F4N5O3 W: 479.43
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly select
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.